PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Webcasts|March 26, 2020
How to Perform Ignition and Drying Methods Such as USP and USP More Safely Without Sacrificing Performance
Author(s)CEM
Join Ian Olmsted, PhD, to learn how you can perform ignition and drying methods more safely, without sacrificing data quality or workflow. He will explore the hazards associated with sulfated ashing and moisture content analysis in the pharmaceutical industry. Live: Thursday, Mar. 26, 2020 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET On demand available after airing until Mar. 26, 2021 Register free
Register free:
Event Overview:
Pharma regulations require sulfated ashing and moisture analysis to accurately determine formulation. Examples include analysis of inorganic impurities in organic fillers and moisture content in final pill products. Historically, both of these methods have been manually performed with high risks to both personal safety and data quality.
Traditional sulfated ash methods bring an additional level of risk due to exposure to acid, acid vapors, and open flame. Reducing exposure to harmful conditions without sacrificing test quality should be the focus of any pharmaceutical company. In this webinar, a safer, more accurate means to determine both ash and moisture content will be discussed.
- Pre-ash is completed inside muffle furnace without user input, removing exposure to open flame
- Acid vapors are automatically neutralized and removed from the lab, reducing exposure to personnel and lab equipment
- Both moisture and ash analysis are completed without exposure to hot surfaces or volatile sample components
- With minimal user input, automated test methods reduce error
Key Learning Objectives:
- Analyze ash and moisture more accurately and safely
- Learn how to improve lab efficiency with automated testing
- Determine how to reduce safety risks in your lab
Speaker: Ian Olmsted, Product Manager, Process Control Division, CEM Corporation
Time and date: Thursday, Mar. 26, 2020 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET
On demand available after airing until Mar. 26, 2021
Sponsor: CEM
Register free:
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Trending on Pharmaceutical Technology
1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
Symptomatic Dermographism: Novartis Lands Remibrutinib Label Expansion
4
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
5